#61: Oscient Pharmaceuticals Seeks to Improve Capital Structure through Proposed Exchange Offer with Holders of its 3.50% Convertible Senior Notes due 2011
Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) today announced that
it has filed a registration statement with the Securities and Exchange
Commission relating to a...
Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) will participate in
the BMO Capital Markets Focus on Healthcare Conference on Tuesday,
August 5, 2008 in New York...
Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) will participate in
the Roth Capital Partners 20th Annual OC Growth
Conference on Thursday, February 21, 2008 in Dana Point,...
Awareness Brings Added ValueComments made in this release are those of Maybach Financial Group and any questions or comments should be directed to the contact information located at the...
Oscient Pharmaceuticals Corporation (Nasdaq:OSCI) will release financial results for the third quarter ended September 30, 2007 on Wednesday, October 31, 2007 prior to the opening of the...
Revenues increase approximately 25 percent from third quarter of 2006; Nine month revenues increase approximately 96 percent from prior year reflecting ANTARA® acquisition
Oscient...
Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) will participate in the Natixis Bleichroeder Hidden Gems Conference on Monday, October 8, 2007 in New York City. The Company’s President...
WALTHAM, Mass.--(BUSINESS WIRE)--Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) today announced that it has commenced offers to exchange up to $185,600,000 aggregate principal...
#53: OSCI News Oscient Pharmaceuticals Files Registration Statements for Proposed Exchange Offers with Holders of its Convertible Notes and an Offering of up to $30,000,000 Principal Amount of New 3.50% Convertible Senior Notes due 2011
WALTHAM, Mass.--(BUSINESS WIRE)--Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) today announced that it has filed registration statements with the Securities and Exchange Commission...
WALTHAM, Mass.--(BUSINESS WIRE)--Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) will participate in the Cowen & Company 27th Annual Healthcare Conference on Thursday, March 15,...
MONTREAL and WALTHAM, Mass.--(BUSINESS WIRE)--Abbott Canada, the Canadian affiliate of Abbott, has launched Oscient Pharmaceuticals Corporation’s (Nasdaq: OSCI) fluoroquinolone...
WALTHAM, Mass.--(BUSINESS WIRE)--Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) today reported financial results for the fourth quarter and fiscal year ended December 31, 2006. The...
WALTHAM, Mass.--(BUSINESS WIRE)--Oscient Pharmaceuticals Corporation (Nasdaq:OSCI) will release financial results for the fourth quarter and fiscal year ended December 31, 2006 on...
WALTHAM, Mass.--(BUSINESS WIRE)--Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) today announced
preliminary revenue results for the fourth quarter and fiscal year ended
December...